NASDAQ:ATAI

Ata Stock Insider Trading

Healthcare > Biotechnology

Buy ATAI

*Your capital is at risk

$4.53

-0.280 (-5.82%)

At Close: Jun 03, 2026

ATA Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.09. In total, the insiders bought 50.41M and sold 700.8K ATAI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.09
● Buy	50.41M shares
● Sell	700.8K shares
87% Buy Activity Moderate Positive Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.09. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (87% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Craig Kevin James Chief Medical Officer	Officer	20 000 Value: $29.6K
Mar 14, 2025 Buy	Common Shares M-Exempt	Short Glenn Frank Chief Scientific Officer	Officer	32 500 Value: $48.1K
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Short Glenn Frank Chief Scientific Officer	Officer	32 500 Value: $48.1K
Mar 14, 2025 Buy	Common Shares M-Exempt	Rao Srinivas See Remarks	Officer	175 000 Value: $259.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Rao Srinivas See Remarks	Officer	175 000 Value: $259.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Kirpekar Sahil Chief Business Officer	Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Kirpekar Sahil Chief Business Officer	Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Kirpekar Sahil Chief Business Officer	Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Kirpekar Sahil Chief Business Officer	Officer	100 000 Value: $148.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Rao Srinivas See Remarks	Officer	175 000 Value: $259.0K
Mar 14, 2025 Buy	Common Shares M-Exempt	Rao Srinivas See Remarks	Officer	175 000 Value: $259.0K
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Short Glenn Frank Chief Scientific Officer	Officer	32 500 Value: $48.1K
Mar 14, 2025 Buy	Common Shares M-Exempt	Short Glenn Frank Chief Scientific Officer	Officer	32 500 Value: $48.1K
Mar 14, 2025 Buy	Restricted Stock Units M-Exempt	Craig Kevin James Chief Medical Officer	Officer	20 000 Value: $29.6K
Mar 14, 2025 Buy	Common Shares M-Exempt	Craig Kevin James Chief Medical Officer	Officer	20 000 Value: $29.6K
Mar 03, 2025 Buy	Stock Option A-Award	Short Glenn Frank Chief Scientific Officer	Officer	757 915 Value: $1.14M
Mar 03, 2025 Buy	Stock Option A-Award	Craig Kevin James Chief Medical Officer	Officer	757 915 Value: $1.14M
Mar 03, 2025 Buy	Stock Option A-Award	Craig Kevin James Chief Medical Officer	Officer	757 915 Value: $1.14M
Mar 03, 2025 Buy	Stock Option A-Award	Short Glenn Frank Chief Scientific Officer	Officer	757 915 Value: $1.14M
Mar 03, 2025 Buy	Stock Option A-Award	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	757 915 Value: $1.14M
Mar 03, 2025 Buy	Stock Option A-Award	Johnson Anne Nagengast Chief Financial Officer	C-Suite Officer	757 915 Value: $1.14M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ATA INC.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...

Read Full Profile Here